Regentis Biomaterials Ltd.
AMEX: RGNT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Ehud Geller
- Employees
- 10
- Headquarters
- Herzliya, Israel
- IPO year
- 2025
- Market cap
- $16.9M
- Website
- https://www.regentis.co.il
Loading RGNT…
Loading profile data…Frequently asked questions about RGNT
What does Regentis Biomaterials Ltd. (RGNT) do?
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the...
Where does RGNT trade?
Regentis Biomaterials Ltd. (RGNT) trades on the New York Stock Exchange American.
What sector is RGNT in?
Regentis Biomaterials Ltd. (RGNT) operates in the Healthcare sector, specifically in the Medical - Instruments & Supplies industry.
Who is the CEO of Regentis Biomaterials Ltd.?
Ehud Geller is the chief executive officer of Regentis Biomaterials Ltd. (RGNT).
Where is Regentis Biomaterials Ltd. headquartered?
Regentis Biomaterials Ltd. is headquartered in Israel.
Does RGNT pay a dividend?
Regentis Biomaterials Ltd. (RGNT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RGNT go public?
Regentis Biomaterials Ltd. (RGNT) completed its initial public offering in 2025.